Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Adalimumab/etoricoxib

Leishmania donovani infection and lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Lopez-Medina C, et al. Safe Treatment With Secukinumab in a Patient With Axial Spondyloarthritis and a History of a Leishmania donovani Infection. The Journal of Rheumatology 50: 1521-1522, No. 11, Jan 2023. Available from: URL: https://dx.doi.org/10.3899/jrheum.2023-0004 Lopez-Medina C, et al. Safe Treatment With Secukinumab in a Patient With Axial Spondyloarthritis and a History of a Leishmania donovani Infection. The Journal of Rheumatology 50: 1521-1522, No. 11, Jan 2023. Available from: URL: https://​dx.​doi.​org/​10.​3899/​jrheum.​2023-0004
Metadaten
Titel
Adalimumab/etoricoxib
Leishmania donovani infection and lack of efficacy
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-57115-2

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Multiple drugs

Case report

Glesatinib

Case report

Liothyronine

Case report

Vincristine